Jay L. Koyner, MD, is an Associate Professor of Medicine in the Section of Nephrology at the University of Chicago. He completed his undergraduate degree in Biophysics at The Johns Hopkins University. He then went on to complete medical school at the State University of New York at Stony Brook where he awarded a degree with distinction in research following completion of a Howard Hughes Medical Institute Research Fellowship. Dr. Koyner completed his internal medicine and nephrology training at the University of Chicago, where he currently serves as the Medical Director of the Inpatient Dialysis Unit and Director of ICU Nephrology. He is an expert in the care of patients at risk for and diagnosed with acute kidney injury (AKI) . He is spoken nationally and internationally on AKI and a variety of topics in the field of Critical Care Nephrology. Over the last decade he has served many roles for the American Society of Nephrology, including being a member of the Acute Kidney Injury Advisory Group, Co-Director of the Critical Care Nephrology pre-course (2014 to 2018), Co-Editor of the Nephrology Self-Assessment Program (NephSAP) for Acute Kidney Injury and Critical Care Nephrology (2016 to 2019) and currently he sits on the Scientific Advisory Board of the National Kidney Foundation. He has served on the editorial review board of the Clinical Journal of the American Society of Nephrology, The American Journal of Nephrology and Advances in Chronic Kidney Disease. In addition to being a dedicated clinician educator, Dr. Koyner’s critical care nephrology research interests have focused on the utilization of plasma and urine biomarkers to improve patient risk stratification and outcomes in the setting of AKI. He has contributed to several multicenter studies investigating biomarkers of AKI, including the TRIBE-AKI study, the Furosemide Stress Test study and several industry sponsored investigations. More recently he has begun developing and implementing an electronic health record derived AKI risk score, with the goal of improving the care of patients at high risk for the development of severe hospital acquired AKI. He has published over 90 peer-reviewed articles and book chapters on AKI and the care of patients with kidney injury in the ICU.
The University of Chicago
Chicago. IL
- Nephrology
2006
The University of Chicago
Chicago
- Internal Medicine
2004
Stony Brook School of Medicine
Stony Brook, NY
MD - Medicine
2001
The Johns Hopkins University
Baltimore, MD
BA - Biophysics
1996
Artificial intelligence in early detection and prediction of pediatric/neonatal acute kidney injury: current status and future directions.
Artificial intelligence in early detection and prediction of pediatric/neonatal acute kidney injury: current status and future directions. Pediatr Nephrol. 2023 Oct 27.
PMID: 37889281
Biomarker Enrichment in Sepsis Associated Acute Kidney Injury: Finding High-Risk Patients in the ICU.
Biomarker Enrichment in Sepsis Associated Acute Kidney Injury: Finding High-Risk Patients in the ICU. Am J Nephrol. 2023 Oct 16.
PMID: 37844555
Digital health utilities in acute kidney injury management.
Digital health utilities in acute kidney injury management. Curr Opin Crit Care. 2023 12 01; 29(6):542-550.
PMID: 37861196
New biomarkers in acute kidney injury.
New biomarkers in acute kidney injury. Crit Rev Clin Lab Sci. 2023 Sep 05; 1-22.
PMID: 37668397
Digital health and acute kidney injury: consensus report of the 27th Acute Disease Quality Initiative workgroup.
Digital health and acute kidney injury: consensus report of the 27th Acute Disease Quality Initiative workgroup. Nat Rev Nephrol. 2023 Aug 14.
PMID: 37580570
Sepsis-associated acute kidney injury - treatment standard.
Sepsis-associated acute kidney injury - treatment standard. Nephrol Dial Transplant. 2023 Jul 03.
PMID: 37401137
Intraoperative Renal Replacement Therapy in Orthotopic Liver Transplantation.
Intraoperative Renal Replacement Therapy in Orthotopic Liver Transplantation. Adv Kidney Dis Health. 2023 07; 30(4):378-386.
PMID: 37657884
Real-World Use of AKI Biomarkers: A Quality Improvement Project Using Urinary Tissue Inhibitor Metalloprotease-2 and Insulin-Like Growth Factor Binding Protein 7 ([TIMP-2]*[IGFBP7]).
Real-World Use of AKI Biomarkers: A Quality Improvement Project Using Urinary Tissue Inhibitor Metalloprotease-2 and Insulin-Like Growth Factor Binding Protein 7 ([TIMP-2]*[IGFBP7]). Am J Nephrol. 2023; 54(7-8):281-290.
PMID: 37356428
Study protocol of a phase 2, randomised, placebo-controlled, double-blind, adaptive, parallel group clinical study to evaluate the efficacy and safety of recombinant alpha-1-microglobulin in subjects at high risk for acute kidney injury following open-chest cardiac surgery (AKITA trial).
Study protocol of a phase 2, randomised, placebo-controlled, double-blind, adaptive, parallel group clinical study to evaluate the efficacy and safety of recombinant alpha-1-microglobulin in subjects at high risk for acute kidney injury following open-chest cardiac surgery (AKITA trial). BMJ Open. 2023 04 06; 13(4):e068363.
PMID: 37024249
Predicting the Development of Renal Replacement Therapy Indications by Combining the Furosemide Stress Test and Chemokine (C-C Motif) Ligand 14 in a Cohort of Postsurgical Patients.
Predicting the Development of Renal Replacement Therapy Indications by Combining the Furosemide Stress Test and Chemokine (C-C Motif) Ligand 14 in a Cohort of Postsurgical Patients. Crit Care Med. 2023 Aug 01; 51(8):1033-1042.
PMID: 36988335
Mid-Career Award
American Society of Nephrology
2019